SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (1095)3/18/2003 8:47:12 AM
From: NeuroInvestment  Respond to of 1834
 
I have been following Hypnion for about two years now, and like their screening technology. Their benchmark for insomnia has been Ambien (they are using Provigil as the alertness/circadian disorder comparator), which is not going to remain the state of the art option. Even provided that they do come up with a competitive insomnia drug, my quick guesstimate for a best-case marketing timeframe is 2009-10.Thus, as you note, it is 'early to worry'.

Harry Tracy
NeuroInvestment


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News